Bingshan Liu
Medical Monitor
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Bingshan Liu as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 00:35 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT03992339 · A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed/Refractory Diffuse Large B-Cell LymphomaAntengene Corporation · completed · Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 00:35 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 00:35 UTC. The ranking covers the 200 most relevant of 795 PubMed records, and a shared surname and initials can bring in a namesake. All 795 on PubMed
- Tirzepatide Once Weekly for the Treatment of Obesity.N Engl J Med · 20222,989 citationsRCR 267.8
- Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.Lancet · 20202,489 citationsRCR 131.1
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.N Engl J Med · 20211,646 citationsRCR 108.9
- Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.Lancet Oncol · 20211,003 citationsRCR 54.5
- Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis.N Engl J Med · 2019495 citationsRCR 21.8
- 488 citationsRCR 21.1
- Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial.Cancer Cell · 2022462 citationsRCR 28.6
- 441 citationsRCR 52.6
- Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions.N Engl J Med · 2023368 citationsRCR 29.4
- 294 citationsRCR 14.4